Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. has announced a definitive agreement for a registered direct offering, raising a total of $7.1 million, which includes an upfront payment of $2.5 million and the potential for an additional $4.6 million through the exercise of short-term warrants. The offering involves the sale of 825,085 shares of common stock at a price of $3.03 per share and is expected to close on or about April 16, 2026. H.C. Wainwright & Co. is serving as the exclusive placement agent for this transaction.

Acurx Pharmaceuticals, based in Staten Island, New York, is a late-stage biopharmaceutical company focused on developing a novel class of antibiotics aimed at treating difficult bacterial infections. The company’s lead product candidate, ibezapolstat, is designed to target Gram-positive bacteria, including those responsible for Clostridioides difficile infections, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE). The funds raised from this offering are intended for working capital and general corporate purposes, which may include advancing the clinical development of ibezapolstat, particularly as it prepares for Phase 3 trials.

The offering is being conducted at-the-market, adhering to Nasdaq rules, which allows Acurx to raise capital without significantly diluting existing shareholders. The concurrent issuance of unregistered short-term warrants, which can potentially double the number of shares available for purchase, adds a layer of complexity to the transaction. The warrants are immediately exercisable and will expire 24 months after the registration statement becomes effective, providing investors with a short-term opportunity to increase their stake in the company.

The biopharmaceutical sector is currently experiencing heightened interest and investment, particularly in companies developing innovative therapies for antibiotic-resistant infections. Acurx's strategic focus on Gram-positive selective antibiotics positions it well within this growing market, as healthcare providers and regulators increasingly prioritize solutions to combat resistant bacterial strains. The successful execution of this offering could enhance Acurx's ability to advance its clinical programs and solidify its market position.

In summary, Acurx Pharmaceuticals' recent fundraising initiative reflects broader trends in the biopharmaceutical industry, where companies are actively seeking capital to support the development of critical therapies. As antibiotic resistance remains a significant public health challenge, the outcomes of Acurx's clinical trials and the effective deployment of the raised funds will be closely monitored by investors and industry stakeholders alike. The implications of this offering could extend beyond Acurx, influencing investor sentiment and funding dynamics across the biopharmaceutical landscape.